MF63

MF63 is a selective and orally active inhibitor of mPGES-1. MF63 reduces the accumulation of PGE2, relieves pyresis, hyperalgesia, and inflammatory pain by inhibiting mPGES-1[1].

Product Specifications

CAS Number

[892549-43-8]

UNSPSC

12352005

Target

PGE synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/MF63.html

Purity

99.55

Solubility

DMSO : 75 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=CC(C2=C3C=CC=C2)=C(C4=C3N=C(C5=C(C=CC=C5C#N)C#N)N4)C=C1

Molecular Formula

C23H11ClN4

Molecular Weight

378.81

References & Citations

[1]Xu D, et al. MF63 [2- (6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl) -isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 2008 Sep;326 (3) :754-63. |[2]Tuure L, et al. Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. Br J Pharmacol. 2020 Sep;177 (18) :4134-4146.